Effects of schisandrin B on pharmacokinetics of doxorubicin in rats

To investigate the effect of combination of schisandrin B and doxorubicin on the pharmacokinetic behavior of doxorubicin in SD rats. An LC-MS/MS method was established for the determination of doxorubicin and its main metabolite doxorubicinol in SD rats plasma. Separation was performed on Agilent Eclipse XDB-C1S column (100 mm x2. 1 mm, 3. 5 jun) using 0. 1 % formic acid solution and acetonitrile as mobile phase with a liner gradient program. The ion transitions were performed under ESI position model at rn/z 544. 2-? 397. 3 (doxorubicin), m/z 546. 2->399. 2 (doxorubicinol), rn/z 528. 2-?SSI. 2 (daunorubicin, internal standard). Calibration curves of doxorubicin (0.500-500 ng/mL) and doxorubicinol (0.200-50.0 ng/mL) showed good linear regression. The precision and accuracy met the requirements. The variation coefficient of extraction recovery and matrix effect was less than 15%. The AUC0t of doxorubicin were (605.69 ± 145.84) and (564.53 ± 23. 99) ng-h/mL in alone and combined group, respectively. The AUC04 of doxorubicinol were (26. 69 ± 13. 41) and (29. 00 ±2. 78) ng-h/mL, respectively. Results indicated that, schisandrin B had not affected the pharmaco-kinetic behavior of doxorubicin in SD rats.